Efter 3. dosis udviklede 92- 99% af spædbørnene > 1, 0 µg/ ml anti- PRP.
Post-dose 3, 92% to 99% of infants developed > 1.0 µg/ ml of anti-PRP, a level associated with long- term protection against invasive Hib disease, and the GMTs ranged from 7.7 µg/ ml to 14.0 µg/ ml.